Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
IRIDEX CORP reported the year ended December 30, 2023 results: revenue $51.9 million.
- Period
- the year ended December 30, 2023
- Revenue
- $51.9 million
- Result
- reported results
Exact text from the filing
Revenue for the year ended December 30, 2023 was $51.9 million compared to $57.0 million in 2022.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
IRIDEX CORP reported the fourth quarter ended December 30, 2023 results: revenue $12.5 million, net income Net loss for the fourth quarter of 2023 was $3.0 million, EPS $0.18 per share.
- Period
- the fourth quarter ended December 30, 2023
- Revenue
- $12.5 million
- Net income
- Net loss for the fourth quarter of 2023 was $3.0 million
- EPS
- $0.18 per share
- Result
- reported results
Exact text from the filing
Revenue for the three months ended December 30, 2023 was $12.5 million compared to $15.2million during the same period of the prior year. Retina product revenue decreased 7% compared to the prior year period to $7.5 million. Total product revenue from the Cyclo G6 glaucoma product group was $3.0 million, a decrease of $1.2 million versus the fourth quarter of 2022. Other revenue decreased to $2.0 million in the fourth quarter of 2023 compared to the prior year period of $2.9 million, primarily driven by decreased royalties due to expiration of licensed patents and lower service revenue. Fourth quarter revenue was impacted by several factors. In the retina business, deferral of capital purchases led to lower system sales in the U.S. and internationally, international distributors destocked inventory in advance of new laser platform launches and to minimize any potential impact from transactions resulting from Iridex’s strategic review. The Company experienced isolated supply chain limit
View on SEC.gov